Advisory Committee Chair
Xiaoguang Margaret Liu
Advisory Committee Members
Gangjian Qin
Lufang Zhou
Runhua Liu
Wuqiang Zhu
Document Type
Dissertation
Date of Award
2018
Degree Name by School
Doctor of Philosophy (PhD) School of Engineering
Abstract
Cancer is one of the leading causes of mortality globally, and multiple anti-cancer therapies have been developed and applied over last few decades. Antibody-based cancer therapies have been on one of the most exciting and promising therapeutic strategies. Monoclonal antibodies (mAbs) can control the progression of cancers via targeted binding to the specific antigen of tumors to trigger an immune response, target and block the signaling pathway involved in cancer progression, or deliver cytotoxic agents into tumors. Two chimeric/humanized monoclonal antibodies (anti-HER2 mAb and anti-CD 20 mAb) with higher efficacy were successfully expressed in engineered Chinese Hamster Ovary Cells (CHO). A robust platform was established and optimized for large-scale, high quality mAbs manufacturing. The in vitro studies, e.g. binding affinity of antibody to cancer cells were performed to evaluate the bio-function of the antibody produced in stirred-tank bioreactor. In addition, advanced Omics technologies, e.g. proteomics, were used to identify novel surface markers, enrich the knowledge of cellular metabolism and physiology, and guide cell engineering and bioprocess optimization. The antibody production platform and the deep understating of antibody expression regulation can also benefit the development of other promising antibody-based therapies (e.g. antibody-drug conjugate and antibody-based cell therapy) in the future.
Recommended Citation
Xu, Ningning, "Novel Anti-Cancer Therapy Development Using Omics Guided Rational Cell Process Engineering" (2018). All ETDs from UAB. 3391.
https://digitalcommons.library.uab.edu/etd-collection/3391
